You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSS mCRC

Showing 1 - 25 of 483
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)

Recruiting
  • Colorectal Neoplasms
  • hypofractionation Radiotherapy
  • +3 more
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Mar 28, 2022

Metastatic Colorectal Cancer Trial in Providence (Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201

Terminated
Has Results
  • Metastatic Colorectal Cancer
  • Dose level 1 ONC201 625mg
  • +2 more
  • Providence, Rhode Island
    Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals
May 25, 2022

New Patient Stratification Tools in MSS RAS mt mCRC

Completed
  • Advanced Colorectal Cancer
    • Heidelberg, Germany
    • +9 more
    Nov 25, 2022

    CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at

    Withdrawn
    • CCR5
    • +3 more
    • 700mg leronlimab weekly dose
    • +3 more
    • (no location specified)
    Feb 15, 2023

    Metastatic Colorectal Cancer, MSS Trial in Heidelberg (Pembrolizumab, Maraviroc)

    Completed
    Has Results
    • Metastatic Colorectal Cancer
    • MSS
    • Heidelberg, Germany
      National Center for Tumor Diseases, University Hospital Heidelbe
    May 17, 2022

    Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • mCRC
    • Tislelizumab & Fruquintinib
    • Guangzhou, Guangdong, China
    • +1 more
    Jan 25, 2023

    NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low

    Recruiting
    • NSCLC
    • +2 more
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Mar 28, 2022

    Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)

    Recruiting
    • Metastatic Microsatellite-stable Colorectal Cancer
    • Experimental drug
    • Control Rx
    • Hefei, Anhui, China
    • +11 more
    Mar 13, 2023

    Metastatic Microsatellite Stable Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab, Radiation Therapy)

    Recruiting
    • Metastatic Microsatellite Stable Colorectal Cancer
    • Boston, Massachusetts
    • +2 more
    Apr 27, 2021

    Colon Cancer Trial in United States (Panitumumab, Nivolumab, Ipilimumab)

    Active, not recruiting
    Has Results
    • Colon Cancer
    • Tampa, Florida
    • +4 more
    Nov 10, 2021

    Metastatic Colorectal Cancer Trial in Milan (Temozolomide, Nivolumab, Ipilimumab)

    Completed
    • Metastatic Colorectal Cancer
    • Milan, MI, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori
    Apr 1, 2022

    Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston (CXCR1/2

    Recruiting
    • Metastatic Colon Adenocarcinoma
    • +20 more
    • CXCR1/2 Inhibitor SX-682
    • Nivolumab
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 17, 2022

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity Trial in Worldwide (Trilaciclib, Placebo)

    Active, not recruiting
    • Colorectal Cancer Metastatic
    • +2 more
    • Tucson, Arizona
    • +81 more
    Jan 3, 2023

    The mCRC pMMR/MSS or dMMR/MSI-H Status Received Palliative

    Completed
    • Colorectal Cancer Metastatic
    • +2 more
      • Guangzhou, Guangdong, China
        Sun yat-sen university cancer center
      Jul 23, 2020

      Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Dec 4, 2023

      Colorectal Liver Metastases Trial in Nanjing (Radiation: High- and Low-dose radiotherapy, PD-1 Inhibitors)

      Recruiting
      • Colorectal Liver Metastases
      • Radiation: High- and Low-dose radiotherapy
      • PD-1 Inhibitors
      • Nanjing, Jiangsu, China
        Jiangsu Cancer Hospital
      Sep 13, 2023

      Colorectal Cancer, Liver Metastases, MSS Trial (Sinti+Rego+Cele)

      Not yet recruiting
      • Colorectal Cancer
      • +2 more
      • (no location specified)
      Jul 3, 2023

      Colon Cancer, Liver Metastasis Colon Cancer, Rectal Cancer Trial in Ramat Gan (Hepatopulmonary radio-sterilization)

      Not yet recruiting
      • Colon Cancer
      • +2 more
      • Hepatopulmonary radio-sterilization
      • Ramat Gan, Israel
        Sheba Medical Center
      Sep 21, 2023

      Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • Cetuximab + Envafolimab + mFOLFOXIRI
      • Cetuximab + mFOLFOX6/FOLFIRI
      • (no location specified)
      Jul 24, 2023

      MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

      Not yet recruiting
      • MSS
      • Rectal Cancer
      • Sintilimab with Interleukin-2
      • (no location specified)
      Nov 1, 2023

      Metastatic Colorectal Cancer Trial in Milan (Bevacizumab, Irinotecan, Leucovorin)

      Recruiting
      • Metastatic Colorectal Cancer
      • Milan, Italy
        Fondazione IRCCS Istituto Nazionale dei Tumori
      Apr 1, 2022

      Bevacizumab Combined With PD-1 Monoclonal Antibody in

      Not yet recruiting
      • Colorectal Cancer
      • Bevacizumab Combined With PD-1 Monoclonal Antibody
      • (no location specified)
      Nov 8, 2023

      Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

      Completed
      • Colorectal Cancer
      • Fruquintinib combined with anti-PD-1 antibodies
      • ChangSha, Hunan, China
        Hunan Cancer Hospital
      Aug 27, 2023